Identification of a receptor-binding domain in the S protein of the novel human coronavirus middle east respiratory syndrome coronavirus as an essential target for vaccine development

Journal of Virology

Volumn 87, Issue 17, 2013, Pages 9939-9942

  Du, Lanying ^a   Zhao, Guangyu ^b   Kou, Zhihua ^b   Ma, Cuiqing ^a   Sun, Shihui ^b   Poon, Vincent K M ^c   Lu, Lu ^d   Wang, Lili ^a   Debnath, Asim K ^a   Zheng, Bo Jian ^c   Zhou, Yusen ^b   Jiang, Shibo ^a,d  

^a NEW YORK BLOOD CENTER   (United States)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS SPIKE PROTEIN RECEPTOR BINDING DOMAIN FC PROTEIN; NEUTRALIZING ANTIBODY; SPIKE PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CORONAVIRUS; IMMUNOGENICITY; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; RECEPTOR BINDING; RECEPTOR BINDING DOMAIN; SARS CORONAVIRUS; VIRUS NEUTRALIZATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BINDING SITES; CELL LINE; CORONAVIRUS; CORONAVIRUS INFECTIONS; DIPEPTIDYL PEPTIDASE 4; HUMANS; MICE; MICE, INBRED BALB C; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, VIRUS; RESPIRATORY TRACT INFECTIONS; SPIKE GLYCOPROTEIN, CORONAVIRUS; VIRAL VACCINES;

EID: 84883286587     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01048-13     Document Type: Article

References (21)

1. Zaki AM, van BS, Bestebroer TM, Osterhaus AD, Fouchier RA. 2012. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 367:1814-1820.
2. de Groot RJ, Baker SC, Baric RS, Brown CS, Drosten C, Enjuanes L, Fouchier RA, Galiano M, Gorbalenya AE, Memish Z, Perlman S, Poon LL, Snijder EJ, Stephens GM, Woo PC, Zaki AM, Zambon M, Ziebuhr J. 2013. Middle East respiratory syndrome coronavirus (MERS-CoV); announcement of the coronavirus study group. J. Virol. 87:7790-7792.
3. World Health Organization. 17 June 2013. Middle East respiratory syndrome coronavirus (MERS-CoV)-update. World Health Organization, Geneva, Switzerland. http://www.who.int/csr/don/2013_06_17/en/index.html.
4. The Health Protection Agency (HPA) UK Novel Coronavirus Investigation Team. 2013. Evidence of person-to-person transmission within a family cluster of novel coronavirus infections, United Kingdom, February 2013. Euro Surveill. 18:20427.
5. Memish ZA, Zumla AI, Al-Hakeem RF, Al-Rabeeah AA, Stephens GM. 2013. Family cluster of Middle East respiratory syndrome coronavirus infections. N. Engl. J. Med. 368:2487-2494.
6. Peiris JS, Lai ST, Poon LL, Guan Y, Yam LY, Lim W, Nicholls J, Yee WK, Yan WW, Cheung MT, Cheng VC, Chan KH, Tsang DN, Yung RW, Ng TK, Yuen KY. 2003. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361:1319-1325.
7. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, Choe H, Farzan M. 2003. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426:450-454.
8. Wong SK, Li W, Moore MJ, Choe H, Farzan M. 2004. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensinconverting enzyme 2. J. Biol. Chem. 279:3197-3201.
9. He Y, Lu H, Siddiqui P, Zhou Y, Jiang S. 2005. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J. Immunol. 174:4908-4915.
10. Du L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S. 2009. The spike protein of SARS-CoV: a target for vaccine and therapeutic development. Nat. Rev. Microbiol. 7:226-236.
11. Arnold K, Bordoli L, Kopp J, Schwede T. 2006. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 22:195-201.
12. Prabakaran P, Gan J, Feng Y, Zhu Z, Choudhry V, Xiao X, Ji X, Dimitrov DS. 2006. Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody. J. Biol. Chem. 281:15829-15836.
13. Jiang S, Lu L, Du L, Debnath AK. 2013. A predicted receptor-binding and critical neutralizing domain in S protein of the novel human coronavirus HCoV-EMC. J. Infect. 66:464-466.
14. Li F, Li W, Farzan M, Harrison SC. 2005. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 309: 1864-1868.
15. Raj VS, Mou H, Smits SL, Dekkers DH, Muller MA, Dijkman R, Muth D, Demmers JA, Zaki A, Fouchier RA, Thiel V, Drosten C, Rottier PJ, Osterhaus AD, Bosch BJ, Haagmans BL. 2013. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 495:251-254.
16. Du L, Zhao G, He Y, Guo Y, Zheng BJ, Jiang S, Zhou Y. 2007. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. Vaccine 25:2832-2838.
17. Du L, Zhao G, Sun S, Zhang X, Zhou X, Guo Y, Li Y, Zhou Y, Jiang S. 2013. A critical HA1 neutralizing domain of H5N1 influenza in an optimal conformation induces strong cross-protection. PLoS One 8:e53568. doi: 10.1371/journal.pone.0053568.
18. Du L, Zhao G, Chan CC, Sun S, Chen M, Liu Z, Guo H, He Y, Zhou Y, Zheng BJ, Jiang S. 2009. Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity. Virology 393:144-150.
19. Gierer S, Bertram S, Kaup F, Wrensch F, Heurich A, Kramer-Kuhl A, Welsch K, Winkler M, Meyer B, Drosten C, Dittmer U, von HT, Simmons G, Hofmann H, Pohlmann S. 2013. The spike-protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2 and is targeted by neutralizing antibodies. J. Virol. 87:5502-5511.
20. Du L, Ma C, Jiang S. 2013. Antibodies induced by receptor-binding domain in spike protein of SARS-CoV do not cross-neutralize the novel human coronavirus hCoV-EMC. J. Infect. S0163-4453(13)00111- 4. doi: 10.1016/j.jinf.2013.05.002.
21. Bisht H, Roberts A, Vogel L, Bukreyev A, Collins PL, Murphy BR, Subbarao K, Moss B. 2004. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc. Natl. Acad. Sci. U. S. A. 101:6641-6646